Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Treatment of Central Retinal Artery Occlusion with Intravenous Thrombolysis
    STROKE ALERT

    Treatment of Central Retinal Artery Occlusion with Intravenous Thrombolysis

    August 1, 2020
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Tenecteplase vs. Alteplase for Thrombolysis in Basilar Artery Occlusion

    Endovascular Treatment for Acute Basilar Artery Occlusion Is Safe and Effective

    Intracranial Clot Extraction Results in Better Outcomes than Intravenous Thrombolysis Alone

    Related Products

    Intracranial Clot Extraction Results in Better Outcomes than Intravenous Thrombolysis Alone

    Carotid Occlusion Rarely Develops from Asymptomatic Carotid Artery Stenosis

    Basilar Artery Thrombectomy Can Be Accomplished with Acceptable Outcomes

    Keywords

    artery

    Vision

    intravenous

    alteplase

    crao

    By Matthew E. Fink, MD

    Louis and Gertrude Feil Professor and Chair, Department of Neurology, Associate Dean for Clinical Affairs, New York Presbyterian/Weill Cornell Medical College

    Dr. Fink reports no financial relationships relevant to this field of study.

    SOURCE: MacGrory B, Nackenoff A, Poli S, et al. Intravenous fibrinolysis for central retinal artery occlusion. A cohort study and updated patient-level meta-analysis. Stroke 2020;51:2018-2025.

    Central retinal artery occlusion (CRAO) is a serious threat to vision caused by interruption of the blood supply to the retina and leading to sudden, painless loss of vision in one eye. For 30 years there have been anecdotal reports and small case series suggesting that intravenous thrombolysis might be beneficial in this disorder, but none of the stroke treatment guidelines have incorporated thrombolysis as definitive treatment for this disorder. At the present time, there is no effective treatment that has been proven to salvage vision in patients with CRAO.

    The investigators in this study enrolled consecutive patients with acute CRAO within 48 hours of symptom onset who had a visual acuity < 20/200. This was an open-label trial, and there was no randomization. Patients were treated per the local treating physician. The primary outcomes were safety and functional visual recovery. Rates of recovery were compared for those treated with alteplase within 4.5 hours of symptom onset to those who did not receive alteplase, including a comparison with untreated patients who presented within the window for potential thrombolytic treatment, or 4.5 hours from onset of symptoms. Cases were collected from several different medical centers, and the protocols for treatment varied considerably from different centers.

    The principal investigators enrolled 112 patients into the prospective cohort, of whom 25 (22.3%) were treated with intravenous alteplase. One patient had an asymptomatic brain hemorrhage after alteplase treatment. Forty-four percent of patients treated with alteplase had recovery of visual acuity if treated within 4.5 hours of symptom onset compared to 13.1% of those who were not treated with alteplase (P = 0.003) and 11.6% of those who arrived within four hours of symptom onset but did not receive alteplase. In a meta-analysis of 238 patients from multiple centers, including 67 patients treated with alteplase within 4.5 hours of symptom onset, the recovery rate for vision was 37.3%. Those who were not treated with intravenous alteplase had a 17.7% rate of recovery.

    The authors concluded that administration of intravenous alteplase within 4.5 hours of onset of symptoms results in a much higher likelihood of a favorable visual outcome for patients who have acute CRAO. A randomized, prospective, placebo-controlled clinical trial is strongly recommended to determine definitively if this treatment is beneficial.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 39, No. 12) - August 2020
    August 1, 2020

    Table Of Contents

    Clinical Trials of IL-6 Inhibitors for the Treatment of Neuromyelitis Optica Spectrum Disorders

    Brachial Plexopathy Localization in Patients with Cancer

    Anticoagulation in Patients with Ischemic Stroke Related to Atrial Fibrillation, Following Reperfusion Therapy

    Treatment of Central Retinal Artery Occlusion with Intravenous Thrombolysis

    Widely Used in Asia, Cilostazol Appears Effective for Long-Term Secondary Stroke Prevention

    Should Patients with Ischemic Stroke and Large Vessel Occlusions Go Directly to Endovascular Thrombectomy?

    Mobile Stroke Units: What Is the Best Way to Use Them?

    COVID-19 Infection Increases Stroke Risk by Almost Eight Times the Stroke Risk with Influenza

    Ticagrelor Added to Aspirin Reduces Long-Term Risk of Recurrent Stroke or Death After Ischemic Stroke or TIAs

    We’d Love to Hear from You!

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Editorial Group Manager Leslie Coplin; Editor Jason Schneider; Executive Editor Shelly Morrow Mark; and Accreditations Director Amy M. Johnson, MSN, RN, CPN, report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2021 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing